LEADER 01543nam  2200337z- 450 
001 9910689876503321
005 20160827193720.0
035   $a(CKB)5860000000022924
035   $a(BIP)012480527
035   $a(EXLCZ)995860000000022924
100   $a20220406c2004uuuu  -u-         -
101 0 $aeng
200 10$aFDA's role in protecting the public health $eexamining FDA's review of safety and efficacy concerns in anti-depressant use by children : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighth Congress, second session, September 23, 2004
215   $a1 online resource (iii, 633 p.) $cill
311   $a0-16-074327-3 
517   $aFDA's Role in Protecting the Public Health
606   $aDepression in children$xChemotherapy$xGovernment policy$zUnited States
606   $aAntidepressants$xGovernment policy$zUnited States
606   $aAntidepressants$xEffectiveness$zUnited States
610   $aDepression in children
610   $aAntidepressants
610   $aPsychology
610   $aMedical
615  0$aDepression in children$xChemotherapy$xGovernment policy
615  0$aAntidepressants$xGovernment policy
615  0$aAntidepressants$xEffectiveness
712 02$aUnited States, Congress House Committee on Energy and Commerce Subcommittee on Oversight and Investigations Staff,$4oth
906   $aBOOK
912   $a9910689876503321
996   $aFDA's role in protecting the public health$93142202
997   $aUNINA